Defactinib (PF-04554878) |
|
| Synonyms: N-Methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]benzamide; VS 6063 | |
| Cat. No.: D99600 | CAS No.: 1073154-85-4 |
| MDL.: | Formula: C20H21F3N8O3S |
| F.W.510.49 | Purity: 99％ |
| Storage: | |
| Size/Unit | Price | Qty | Availability | Price Total |
|---|---|---|---|---|
| 1mg | POA | Enter qty and click checkbox |
| Catalog Number： | D99600 | CAS No.: | 1073154-85-4 | |
| MDL: | Formula: | C20H21F3N8O3S | ||
| F.W.: | 510.49 | Purity: | 99％ | |
| Package: | Unit: | mg | ||
| Appearance: | M.P.: | |||
| B.P.: | Density: | |||
| Optical Rotation: | Refractive Index: | |||
| Solubility: | Stability: | |||
| Storage: | Category: | Reference Standard | ||
| Reference: | O’Brien, S. et al.: Oncotarget., 5, 7945 (2014); Kang, Y. et al.: J. Natl. Cancer Inst., 105, 1485 (2013); | |||
| Application: | Defactinib is a selective and orally active FAK inhibitor phase 2. Used in treating cancer patients as it decreases proliferation and increases apoptosis. | |||
| Category: | ||||